IL302651A - Integrin inhibitors and their uses - Google Patents
Integrin inhibitors and their usesInfo
- Publication number
- IL302651A IL302651A IL302651A IL30265123A IL302651A IL 302651 A IL302651 A IL 302651A IL 302651 A IL302651 A IL 302651A IL 30265123 A IL30265123 A IL 30265123A IL 302651 A IL302651 A IL 302651A
- Authority
- IL
- Israel
- Prior art keywords
- crystalline form
- water content
- degrees
- theta
- peaks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302651A true IL302651A (en) | 2023-07-01 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302651A IL302651A (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitors and their uses |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12018025B2 (enExample) |
| EP (1) | EP4247472A4 (enExample) |
| JP (1) | JP2023550428A (enExample) |
| KR (1) | KR20230121761A (enExample) |
| CN (1) | CN116710169A (enExample) |
| AU (1) | AU2021381516A1 (enExample) |
| CA (1) | CA3173755A1 (enExample) |
| CL (1) | CL2023001418A1 (enExample) |
| CO (1) | CO2023006522A2 (enExample) |
| CR (1) | CR20230262A (enExample) |
| CU (1) | CU20230026A7 (enExample) |
| DO (1) | DOP2023000101A (enExample) |
| EC (1) | ECSP23045278A (enExample) |
| IL (1) | IL302651A (enExample) |
| JO (1) | JOP20230102A1 (enExample) |
| MX (1) | MX2023005889A (enExample) |
| PE (1) | PE20240114A1 (enExample) |
| TW (1) | TW202235417A (enExample) |
| WO (1) | WO2022109598A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| US11419869B2 (en) | 2019-04-08 | 2022-08-23 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| CN120091811A (zh) * | 2022-07-09 | 2025-06-03 | 普利安特治疗公司 | 整合素抑制剂及其与其它药剂组合的用途 |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
| WO2025072206A1 (en) * | 2023-09-25 | 2025-04-03 | Pliant Therapeutics, Inc. | Integrin inhibitors for treatment of primary sclerosing cholangitis |
| TW202535400A (zh) | 2023-12-14 | 2025-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2025217571A1 (en) * | 2024-04-12 | 2025-10-16 | Pliant Therapeutics, Inc. | Fixed dose combinations of integrin inhibitor with ppar agonists |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| SG11201907820SA (en) | 2017-02-28 | 2019-09-27 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| LT3761980T (lt) | 2018-03-07 | 2024-03-12 | Pliant Therapeutics, Inc. | Aminorūgščių junginiai ir jų panaudojimo būdai |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020016704A1 (ja) * | 2018-07-20 | 2020-01-23 | 株式会社半導体エネルギー研究所 | 撮像パネル、撮像装置 |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| ES3027421T3 (en) | 2018-08-29 | 2025-06-13 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3903316A1 (en) * | 2018-12-28 | 2021-11-03 | LunaPBC | Community data aggregation, completion, correction, and use |
| EP3923857B8 (en) * | 2019-02-15 | 2024-04-17 | Clean Bite, LLC | Oral hygiene appliance |
| US11419869B2 (en) * | 2019-04-08 | 2022-08-23 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| EP4058481A1 (en) | 2019-11-15 | 2022-09-21 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
| CN115989235A (zh) | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| TWI838626B (zh) * | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2022087224A1 (en) * | 2020-10-21 | 2022-04-28 | Cohbar, Inc. | Method of treating fibrosis with a combination therapy |
| CA3173787A1 (en) | 2021-04-30 | 2022-11-03 | Scott Turner | Expanded dosage regimens for integrin inhibitors |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| EP4416147A1 (en) | 2021-10-14 | 2024-08-21 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en not_active Abandoned
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en not_active Ceased
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A4/en not_active Withdrawn
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko not_active Withdrawn
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
-
2023
- 2023-05-08 JO JOJO/P/2023/0102A patent/JOP20230102A1/ar unknown
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
-
2024
- 2024-03-27 US US18/619,017 patent/US20240391914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230262A (es) | 2023-07-26 |
| PE20240114A1 (es) | 2024-01-22 |
| CU20230026A7 (es) | 2024-01-10 |
| ECSP23045278A (es) | 2023-07-31 |
| EP4247472A1 (en) | 2023-09-27 |
| US12018025B2 (en) | 2024-06-25 |
| US20220177468A1 (en) | 2022-06-09 |
| US20240391914A1 (en) | 2024-11-28 |
| AU2021381516A9 (en) | 2024-10-24 |
| CO2023006522A2 (es) | 2023-06-09 |
| CN116710169A (zh) | 2023-09-05 |
| AU2021381516A1 (en) | 2023-06-22 |
| JP2023550428A (ja) | 2023-12-01 |
| EP4247472A4 (en) | 2024-10-09 |
| CL2023001418A1 (es) | 2023-10-30 |
| DOP2023000101A (es) | 2023-09-29 |
| TW202235417A (zh) | 2022-09-16 |
| MX2023005889A (es) | 2023-06-06 |
| KR20230121761A (ko) | 2023-08-21 |
| WO2022109598A1 (en) | 2022-05-27 |
| CA3173755A1 (en) | 2022-05-27 |
| JOP20230102A1 (ar) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240391914A1 (en) | Integrin inhibitor and uses thereof | |
| IL262030A (en) | Silicone atoms containing analogues of Ivacaptor | |
| IL319761A (en) | Solid forms of 3-((R3,R1)-1-(6,2-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-9,4,3,1-tetrahydro-H2-pyrido[4,3-B]indol-2-yl]2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds containing a substituted phenyl or pyridinyl residue, including methods for using them | |
| IL300051A (en) | The composition containing an arylamide derivative | |
| IL279853B1 (en) | Polymorphic forms of rad 1901-2hcl | |
| IL303519A (en) | Cystic fibrosis treatment methods | |
| JP2024532272A (ja) | 固体型のスピロ三環式ａｐｏｌ１阻害剤およびその使用方法 | |
| IL225808A (en) | Sesquihydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate, process for its preparation and pharmaceutical compositions comprising it for treating diabetes and obesity | |
| IL316068A (en) | Solid-state crystalline forms of N-[4-(6-fluoro-3,4-dihydro-H1-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide | |
| IL272190B (en) | Inhibitors of gamma ror | |
| US11976074B1 (en) | Crystalline salts of Linsitinib | |
| IL285184B1 (en) | Sulcardine salts | |
| IL298984A (en) | Indan compounds, their pharmaceutical preparations and their medical applications | |
| US20180327386A1 (en) | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide | |
| TW201512201A (zh) | 化合物的多晶型及鹽類 | |
| IL275153B1 (en) | Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof | |
| IL322651A (en) | Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile | |
| IL284564B2 (en) | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound | |
| JP2025542317A (ja) | Ｌｐａ１拮抗薬の結晶形態 | |
| IL315654A (en) | Salts of RXR agonists, their crystalline forms and their use | |
| US20250197393A1 (en) | Integrin inhibitor and uses thereof | |
| JP7357634B2 (ja) | Ｕｒａｔ－１阻害剤の新規塩型 | |
| AU2023305541A1 (en) | Integrin inhibitors and uses thereof in combination with other agents | |
| JP7473554B2 (ja) | Ｐａｒ４阻害剤の結晶体 | |
| US20240216352A1 (en) | Lpa1 antagonists for treating interstitial lung disease |